Roche Reports Results of Satralizumab in Second P-III Study for Neuromyelitis Optica Spectrum Disorder

 Roche Reports Results of Satralizumab in Second P-III Study for Neuromyelitis Optica Spectrum Disorder

Roche Reports Results of Satralizumab in Second P-III Study for Neuromyelitis Optica Spectrum Disorder

Shots:

  • The second P-III SAkuraStar study involves assessing of Satralizumab (120 mg) as monothx. vs PBO in97 patients in a ratio (2:1) with AQP4-IgG seropositive or seronegative NMO and AQP4-IgG seropositive NMOSD aged 20-70yrs.
  • The P-III SAkuraStar study results: 55% & 74% reduction in risk of relapse in overall population & AQP4-IgG seropositive patients; relapse free patients in overall population @48 & 96wks. (76.1% & 72.1% vs 61.9% & 51.2%), in AQP4-IgG seropositive (82.9% & 76.5% vs 55.4% & 41.1%) respectively
  • Satralizumab is mAb targeting IL-6 receptor being evaluated in two P-III studies SAkuraStar and SAkuraSky as monothx. & in combination with baseline therapy for NMSOD respectively

Click here to­ read full press release/ article | Ref: Roche | Image: Deviant Art

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post